Cologuard

Definition

Cologuard is a screening test for colon and rectal cancer.

The colon sheds cells from its lining every day. These cells pass with the stool through the colon. Colon cancer cells may have DNA changes in certain genes. Cologuard detects the altered DNA. The presence of abnormal cells or blood in the stool may indicate cancer or precancer tumors.

Alternative Names

Cologuard; Colon cancer screening - Cologuard; Stool DNA test - Cologuard; FIT-DNA stool test; Colon precancer screening - Cologuard

How the Test is Performed

The Cologuard testing kit for colon and rectal cancer must be ordered by your health care provider. It will be sent by mail to your address. You collect the sample at home and send it back to the lab for testing.

The Cologuard testing kit will contain a sample container, a tube, preserving liquid, labels, and instructions on how to collect the sample. When you are ready to have a bowel movement, use the Cologuard testing kit to collect your stool sample.

Read the instructions that come with the testing kit carefully. Wait until you are ready to have a bowel movement. Collect the sample only when it is possible to ship it within 24 hours. The sample must reach the lab in 72 hours (3 days).

Do not collect the sample if:

Follow these steps to collect the sample:

The results of the test will be sent to your provider in two weeks.

How to Prepare for the Test

The Cologuard test does not require any preparation. You do not need to change your diet or medicines before the test.

How the Test will Feel

The test requires you to have a normal bowel movement. It will not feel any different from your regular bowel movements. You can collect the sample at your home privately.

Why the Test is Performed

The test is done to screen for colon and rectal cancer and abnormal growths (polyps) in the colon or rectum.

Your provider may suggest Cologuard testing once every 1 to 3 years starting at age 45 years. The test is recommended if you are age 45 to 75 years and have an average risk of colon cancer. This means that you do not have:

Normal Results

The normal result (negative result) will indicate that:

What Abnormal Results Mean

Abnormal result (positive result) suggests that there may be some pre-cancer or cancer cells in your stool sample. However, the Cologuard test does not diagnose cancer. You will need further tests to make a diagnosis of cancer. Your provider will likely suggest a colonoscopy.

Risks

There is no risk involved in taking the sample for Cologuard test.

Screening tests carry a small risk of:

Considerations

It is unclear yet whether the use of Cologuard will lead to better outcomes compared with other methods used to screen for colon and rectal cancer.

References

Bresalier RS. Colorectal cancer. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 11th ed. Philadelphia, PA: Elsevier; 2021:chap 127.

Centers for Disease Control and Prevention. Colorectal cancer. Reducing risk for colorectal cancer. www.cdc.gov/colorectal-cancer/prevention/. Updated June 12, 2024. Accessed May 15, 2025.

Chu E. Neoplasms of the small and large intestine. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 179.

Eckmann JD, Ebner DW, Bering J, et al, eds. Multitarget stool DNA screening in clinical practice: high positive predictive value for colorectal neoplasia regardless of exposure to previous colonoscopy. Am J Gastroenterol. 2020;115(4):608-615. PMID: 32068535. pubmed.ncbi.nlm.nih.gov/32068535/.

National Comprehensive Cancer Network website. NCCN clinical practice guidelines in oncology (NCCN guidelines): colorectal cancer screening. Version 1.2025 – May 30, 2025. www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Updated May 30, 2025. Accessed June 16, 2025.

Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc. 2022;95(1):1-15. PMID: 34794803 pubmed.ncbi.nlm.nih.gov/34794803/.

Qaseem A, Harrod CS, Crandall CJ, et al. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2023;176(8):1092-1100. PMID: 37523709 pubmed.ncbi.nlm.nih.gov/37523709/.

US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. PMID: 34003218 pubmed.ncbi.nlm.nih.gov/34003218/.



Review Date: 4/21/2025
Reviewed By: Todd Eisner, MD, Private practice specializing in Gastroenterology in Boca Raton and Delray Beach, Florida at Gastroenterology Consultants of Boca Raton. Affiliate Assistant Professor, Florida Atlantic University School of Medicine. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
© 1997- adam.comAll rights reserved.